Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
CONTEXT: Alcohol dependence is a common disorder associated with significant morbidity and mortality. Naltrexone, an opioid antagonist, has been shown to be effective for treatment of alcohol dependence. However, adherence to daily oral pharmacotherapy can be problematic, and clinical acceptance and utility of oral naltrexone have been limited. OBJECTIVE: To determine efficacy and tolerability of a long-acting intramuscular formulation of naltrexone for treatment of alcohol-dependent patients. DESIGN, SETTING, AND PARTICIPANTS: A 6-month, randomized, double-blind, placebo-controlled trial conducted between February 2002 and September 2003 at 24 US public hospitals, private and Veterans Administration clinics, and tertiary care medical centers. Of the 899 individuals screened, 627 who were diagnosed as being actively drinking alcohol-dependent adults were randomized to receive treatment and 624 received at least 1 injection. INTERVENTION: An intramuscular injection of 380 mg of long-acting naltrexone (n = 205) or 190 mg of long-acting naltrexone (n = 210) or a matching volume of placebo (n = 209) each administered monthly and combined with 12 sessions of low-intensity psychosocial intervention. MAIN OUTCOME MEASURE: The event rate of heavy drinking days in the intent-to-treat population. RESULTS: Compared with placebo, 380 mg of long-acting naltrexone resulted in a 25% decrease in the event rate of heavy drinking days (P = .02) [corrected] and 190 mg of naltrexone resulted in a 17% decrease (P = .07). Sex and pretreatment abstinence each showed significant interaction with the medication group on treatment outcome, with men and those with lead-in abstinence both exhibiting greater treatment effects. Discontinuation due to adverse events occurred in 14.1% in the 380-mg and 6.7% in the 190-mg group and 6.7% in the placebo group. Overall, rate and time to treatment discontinuation were similar among treatment groups. CONCLUSIONS: Long-acting naltrexone was well tolerated and resulted in reductions in heavy drinking among treatment-seeking alcohol-dependent patients during 6 months of therapy. These data indicate that long-acting naltrexone can be of benefit in the treatment of alcohol dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structure of Scientific Revolutions
(2017) · Macat Library eBooks · doi:10.4324/9781912281589 · Cited by 5,397
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,806
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Grant, B. F., Dawson, D. A., Stinson, F. S., Chou, S. P., Dufour, M. C., & Pickering, R. P. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.02.004 · Cited by 1,507
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Self-citationA meta-analysis of alcohol consumption and the risk of 15 diseases
Corrao, G. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2003.11.027 · Cited by 1,077
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Alcoholism: Allostasis and Beyond
Koob, G. F. (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000057122.36127.c2 · Cited by 737
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Fleming, M. F. (1997) · JAMA · doi:10.1001/jama.1997.03540370029032 · Cited by 538
Carmen, B., Angeles, M., Ana, M., & María, A. J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00763.x · Cited by 504
Diagnostic value of history in patients with syncope with or without heart disease
Alboni, P., Brignole, M., Menozzi, C., Raviele, A., Del Rosso, A., Dinelli, M., Solano, A., & Bottoni, N. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01241-4 · Cited by 444
Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1758 · Cited by 425
Naltrexone and Alcohol Dependence: Role of Subject Compliance
Volpicelli, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200071010 · Cited by 411
Handling drop‐out in longitudinal studies
Hogan, J. W., Roy, J., & Korkontzelou, C. (2004) · Statistics in Medicine · doi:10.1002/sim.1728 · Cited by 404
Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390
Self-citation(2001) · Survey of Anesthesiology · doi:10.1097/00132586-200108000-00061 · Cited by 360
Chick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310
Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing
Verebey, K., Volavka, J., Mule, S. J., & Resnick, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976203315 · Cited by 270
Patients with Alcohol Problems
O'Connor, P. G., & Schottenfeld, R. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380907 · Cited by 269
Monti, P. M., Rohsenow, D. J., Swift, R. M., Gulliver, S. B., Colby, S. M., Mueller, T. I., Brown, R. A., Gordon, A., Abrams, D. B., Niaura, R. S., et al. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1097/00000374-200111000-00011 · Cited by 233
Streeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228
Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial
Kranzler, H. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00135-9 · Cited by 209
Self-citationMortality and Morbidity Attributable to Use of Addictive Substances in the United States
McGinnis, J. M., & Foege, W. H. (1999) · Proceedings of the Association of American Physicians · doi:10.1046/j.1525-1381.1999.09256.x · Cited by 188
Kranzler, H. R., Wesson, D. R., Billot, L., & DrugAbuse Sciences Naltrexone Depot Study Group (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000130804.08397.29 · Cited by 169
Self-citationEffects of Naltrexone on Alcohol Self-Administration in Heavy Drinkers
Davidson, D., Palfai, T., Bird, C., & Swift, R. (1999) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199902000-00001 · Cited by 165
O'Malley, S. S., Rounsaville, B. J., Farren, C., Namkoong, K., Wu, R., Robinson, J., & O'Connor, P. G. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1695 · Cited by 142
Self-citationPettinati, H. M., Volpicelli, J. R., Pierce, J. D., & O'brien, C. P. (2000) · Journal of Addictive Diseases · doi:10.1300/j069v19n01_06 · Cited by 123
Self-citationUnderstanding US addiction physicians' low rate of naltrexone prescription
Mark, T. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00134-0 · Cited by 120
Addiction Denial and Cognitive Dysfunction: A Preliminary Investigation
Rinn, W., Desai, N., Rosenblatt, H., & Gastfriend, D. R. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.1.52 · Cited by 120
Self-citationSustained‐Release Naltrexone for Alcoholism Treatment: A Preliminary Study
Kranzler, H. R., Modesto‐Lowe, V., & Nuwayser, E. S. (1998) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb03703.x · Cited by 118
Self-citationLittleton, J., & Zieglgänsberger, W. (2003) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2003.tb00492.x · Cited by 110
Evaluating multiple outcomes and gender differences in alcoholism treatment
Schneider, K. M., Kviz, F. J., Isola, M. L., & Filstead, W. J. (1995) · Addictive Behaviors · doi:10.1016/0306-4603(94)00037-y · Cited by 83
Johnson, B. A., Ait‐Daoud, N., Aubin, H., van den Brink, W., Guzzetta, R., Loewy, J., Silverman, B., & Ehrich, E. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000139823.30096.52 · Cited by 82
Self-citationSuperior Outcome of Females Over Males After Brief Treatment for the Reduction of Heavy Drinking
SANCHEZ‐CRAIG, M., LEIGH, G., SPIVAK, K., & LEI, H. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00583.x · Cited by 80
Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach
Volpicelli, J. R., Pettinati, H. M., McLellan, A. T., & O’Brien, C. P. (2001) · Padova Digital University Archive (Ateneo di Padova) · Cited by 70
Self-citationBartus, R. T., Emerich, D. F., Hotz, J., Blaustein, M., Dean, R. L., Perdomo, B., & Basile, A. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300274 · Cited by 69
McCaul, M. E., Wand, G. S., Stauffer, R., Lee, S. M., & Rohde, C. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00241-x · Cited by 68
Medications and alcohol craving.
Swift, R. M. (1999) · PubMed Central · Cited by 59
Clinical evaluation of a naltrexone sustained-release preparation
Chiang, C. N., Hollister, L. E., Gillespie, H. K., & Foltz, R. L. (1985) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(85)90076-6 · Cited by 53
Wang, S., Winchell, C. J., McCormick, C. G., Nevius, S. E., & O’Neill, R. T. (2002) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02486.x · Cited by 33
Women and substance abuse: Treatment modalities and outcomes.
McCrady, B. S., & Raytek, H. S. (1993) · Cited by 32
Cited by
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Self-citationStaphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Metadata
- Authors
- Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-04-06
- Volume
- 293
- Issue
- 13
- Pages
- 1617
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2076078537
- Cited by
- 635
- References
- 45
- FWCI
- 29.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.